BioCryst Pharmaceuticals

Yahoo Finance • 5 months ago

BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) case, it's fantastic news for shareholders. While we would never su... Full story

Yahoo Finance • 8 months ago

12 Best Depressed Stocks To Buy in 2024

In this article, we will take a detailed look at the 12 Best Depressed Stocks To Buy in 2024. For a quick overview of the 5 such stocks, read our article5 Best Depressed Stocks To Buy in 2024. JPMorgan Chief Jamie Dimon, in his latest let... Full story

Yahoo Finance • 12 months ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina has granted approval... Full story

Yahoo Finance • last year

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th in... Full story

Yahoo Finance • last year

BioCryst Launches ORLADEYO® (berotralstat) in Spain

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted marketing authorization for oral, once... Full story

Yahoo Finance • last year

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) leading to a reduction in monthly a... Full story

Yahoo Finance • last year

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options... Full story

Yahoo Finance • last year

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Company builds on deep structure-based drug design capabilities to add protein therapeutics to pipeline: BCX17725 for Netherton syndrome — entering clinic in 2H 2024 Bifunctional fusion protein enabling simultaneous inhibition of multiple... Full story

Yahoo Finance • last year

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

–SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Bi... Full story

Yahoo Finance • last year

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue - - Net cash utilization of $16.5... Full story

Yahoo Finance • 2 years ago

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) institutional shareholders had a great week as one-year returns increased after a 13% gain last week

Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in the company with 51% ownership Ownershi... Full story

Yahoo Finance • 2 years ago

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, including eight percent growth q-o-q— —Over 1,000 U.S. patients on ORLADE... Full story

Yahoo Finance • 2 years ago

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP.... Full story

Yahoo Finance • 2 years ago

Lacklustre Performance Is Driving BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) price-to-sales (or "P/S") ratio of 5.6x might make it look like a strong buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratio... Full story

Yahoo Finance • 2 years ago

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. “I am honored... Full story

Yahoo Finance • 2 years ago

BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman of the board, who recently passed away.... Full story

Yahoo Finance • 2 years ago

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) C... Full story

Yahoo Finance • 2 years ago

BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months— RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmace... Full story

Yahoo Finance • 2 years ago

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

—ORLADEYO net revenue of $70.7 million for Q4 2022 and $251.6 million for FY 2022— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— —ORLADEYO peak sales expected to be $1 billion— RESEARCH TRIANGLE PARK, N.C., Feb... Full story

Yahoo Finance • 2 years ago

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for th... Full story